DE

448.34

+0.13%↑

CTAS

187.33

-0.46%↓

FDX

235.62

+0.69%↑

PAYX

127.47

-0.95%↓

CPRT

44.56

-0.54%↓

DE

448.34

+0.13%↑

CTAS

187.33

-0.46%↓

FDX

235.62

+0.69%↑

PAYX

127.47

-0.95%↓

CPRT

44.56

-0.54%↓

DE

448.34

+0.13%↑

CTAS

187.33

-0.46%↓

FDX

235.62

+0.69%↑

PAYX

127.47

-0.95%↓

CPRT

44.56

-0.54%↓

DE

448.34

+0.13%↑

CTAS

187.33

-0.46%↓

FDX

235.62

+0.69%↑

PAYX

127.47

-0.95%↓

CPRT

44.56

-0.54%↓

DE

448.34

+0.13%↑

CTAS

187.33

-0.46%↓

FDX

235.62

+0.69%↑

PAYX

127.47

-0.95%↓

CPRT

44.56

-0.54%↓

Ocugen Inc

Затворен

1.65

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.61

Максимум

1.71

Ключови измерители

By Trading Economics

Приходи

611K

-15M

Продажби

-108K

1.4M

Марж на печалбата

-1,073.489

Служители

95

EBITDA

724K

-13M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+421.47% upside

Дивиденти

By Dow Jones

Следващи печалби

7.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

181M

500M

Предишно отваряне

1.65

Предишно затваряне

1.65

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.10.2025 г., 23:25 ч. UTC

Значими двигатели на пазара

Salesforce Rises on New FY30 Financial Targets

15.10.2025 г., 18:52 ч. UTC

Печалби
Значими двигатели на пазара

Prologis Shares Gain on Raised Outlook, Data Center Growth

15.10.2025 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software to Buy U.K.'s Tecvia Holding

15.10.2025 г., 17:19 ч. UTC

Придобивния, сливания и поглъщания

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15.10.2025 г., 17:11 ч. UTC

Придобивния, сливания и поглъщания

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15.10.2025 г., 23:48 ч. UTC

Пазарно говорене

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.10.2025 г., 22:37 ч. UTC

Пазарно говорене

Economic Stars Are Aligning for RBA -- Market Talk

15.10.2025 г., 21:44 ч. UTC

Печалби

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15.10.2025 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15.10.2025 г., 20:34 ч. UTC

Печалби

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15.10.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15.10.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15.10.2025 г., 19:06 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Post Back-to-Back Losses -- Market Talk

15.10.2025 г., 18:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15.10.2025 г., 18:23 ч. UTC

Печалби

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15.10.2025 г., 17:37 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15.10.2025 г., 17:34 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15.10.2025 г., 16:57 ч. UTC

Печалби

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15.10.2025 г., 16:51 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Doesn't Disclose Financial Details

15.10.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15.10.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15.10.2025 г., 16:47 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Buys Ikerian

15.10.2025 г., 16:34 ч. UTC

Пазарно говорене

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

421.47% нагоре

12-месечна прогноза

Среден 8.5 USD  421.47%

Висок 15 USD

Нисък 4 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat